On the second day of the 22nd Annual Conference of the National Comprehensive Cancer Network (NCCN), Kilian E. Salerno, MD, of the Roswell Park Cancer Institute, walked the audience through updates to the NCCN Guidelines, explaining clinical situations in which radiation is indicated, appropriate targets of radiation treatment, and optimal approaches for minimizing toxicity.
Recent research has shown the potential of immunotherapy treatments for treating lung cancer, explained Matthew Gubens, MD, MS, assistant clinical professor of thoracic oncology at the University of California, San Francisco. Dr Gubens also spoke about oncologists’ hopes for using immuno-oncology agents in combination with one another or with chemotherapy.
The unique cancer burden among Asian Americans calls for a multifaceted strategy to address these disparities, according to Moon S. Chen Jr, PhD, MPH, professor of hematology and oncology at UC Davis Comprehensive Cancer Center and principal investigator of The National Center for Reducing Asian American Cancer Health Disparities.
While multigene panels are extremely important in precision cancer care, high levels of variance and insufficient insurance coverage are significant barriers to rapid adoption, according to Kenneth Offit, MD, MPH, from Memorial Sloan Kettering Cancer Center.
At the 22nd Annual Conference of the National Comprehensive Cancer Network, held March 23-25, 2017, in Orlando, FL, policy researchers with interest in cancer care disparities discussed the source of existing disparities and how they can be successfully addressed.
It remains unclear why insurers approve some patients for PCSK9 inhibitors while denying others with similar clinical characteristics, according to Seth J. Baum, MD, FACC, FACPM, FAHA, FNLA, FASPC, president of the American Society for Preventive Cardiology, who presented an abstract on the subject at the American College of Cardiology 66th Scientific Session.
The CVD-REAL study presented at the American College of Cardiology 66th Scientific Session asked whether cardiovascular outcomes seen in the EMPA-REG OUTCOME trial could be seen in a real-world environment, and for the entire class of SGLT2 inhibitors, according to AstraZeneca’s Jim McDermott, PhD, vice president for Medical Affairs, Diabetes.
Heart disease is America’s top killer, and people living in poverty are affected at higher rates. With that in mind, the American College of Cardiology devoted devoted a 3-part intensive to this issue at the 66th Scientific Session.
The Million Hearts initiative launched in 2012 set a lofty goal of preventing 1 million cardiovascular deaths in 5 years, but did not quite achieve that target. According to the program ’s executive director, Janet Wright, MD, FACC, Million Hearts will continue to make progress in part due to the solid foundations it has formed in the initial stage.
The Quality Payment Program (QPP) from CMS, including the Medicare Access and CHIP Reauthorization Act (MACRA), represents a shift toward focusing on quality measures, but there are resources available to help clinicians adjust to these changes, explained William Borden, MD, FACC, FAHA, associate professor of medicine and director of healthcare delivery transformation at the George Washington University.
Research from the REACH trial presented at the American College of Cardiology 66th Scientific Session indicated that participants who received the REACH eCounseling intervention showed significant improvements in measures of hypertension management, according to lead study author Rob Nolan, PhD, CPsych, director of Cardiac eHealth at the Peter Munk Cardiac Centre and clinical psychologist and scientist at the Toronto General Research Institute.
Results from the CVD-REAL study seek to answer questions raised by the EMPA-REG OUTCOME study: do the effects of SGLT2 inhibitors on heart failure apply to a broad population?
At the American College of Cardiology Scientific Session, a study of prescriptions for PCSK9 inhibitors confirms what doctors say about trying to get their patients access to the cholesterol drug.
Past study results had raised concerns about the effect of lipid-lowering drugs like evolocumab on cognitive function, but the EBBINGHAUS trial presented at the American College of Cardiology 66th Scientific Session may finally help put those fears to rest, explained lead study author Robert P. Giugliano, MD, MSc, associate professor of medicine at Harvard Medical School.
The study was the first head-to-head trial to compare 2 common options for treatment to prevent recurrent venous thromboembolism.
Coverage from the American College of Cardiology 2017 Scientific Session.
The study's lead author said the findings may show something similar to the "obesity paradox," where high-risk patients fare better than expected due to frequent follow-up by physicians.
The study from Sweden found a substantial benefit for men taking the class of drugs that was discovered by accident when researchers were developing a treatment for angina 2 decades ago.
The study finds that this biomarker can show which patients may develop heart disease even if they have no current blockage or elevated cholesterol levels.
Researchers have identified another high associated with marijuana use: the risk of heart failure and cerebrovascular accidents.
Panel discussion with Gerard F. Anderson, PhD, of Johns Hopkins University; Jenny Bryant of PhRMA; Matt Eyles of AHIP; A. Mark Fendrick, MD, of the University of Michigan Center for Value-Based Insurance Design and co-editor in chief of AJMC; Dan Klein of PAN Foundation; and Grant D. Lawless, RPh, MD, FACP, of University of Southern California. The discussion took place at the Cost-Sharing Roundtable: Sustainable Strategies for Providing Access to Critical Medications. The event was co-hosted by the PAN Foundation and The American Journal of Managed Care®.
A discussion with Jeanne Ireland, advisory board member, District Policy Group and former senior advisor to the Commissioner and Associate Commissioner for Legislation at the FDA, Obama Administration; and The Honorable Dr Phil Gingrey, senior advisor, Drinker Biddle & Reath and District Policy Group and former US Congressman, R-Georgia, 2003-2015. This discussion took place at the Cost-Sharing Roundtable: Sustainable Strategies for Providing Access to Critical Medications. The event was co-hosted by the PAN Foundation and The American Journal of Managed Care®.
Panel discussion moderated by Clifford Goodman, PhD, of The Lewin Group. The discussion took place at the Cost-Sharing Roundtable: Sustainable Strategies for Providing Access to Critical Medication, which was co-hosted by the PAN Foundation and The American Journal of Managed Care®.
Panel discussion moderated by Clifford Goodman, PhD, of The Lewin Group. The discussion took place at the Cost-Sharing Roundtable: Sustainable Strategies for Providing Access to Critical Medication, which was co-hosted by the PAN Foundation and The American Journal of Managed Care®.
Research presented by Jalpa A. Doshi, PhD, associate professor of medicine, director, Economic Evaluations Unit, Center for Evidence-based Practice, and director, Value-based Insurance Design Initiatives, Center for Health Incentives and Behavioral Economics, University of Pennsylvania, the Cost-Sharing Roundtable: Sustainable Strategies for Providing Access to Critical Medications. The event was co-hosted by the PAN Foundation and The American Journal of Managed Care®.
Research presented by Kai Yeung, PharmD, PhD, scientific investigator I, Group Health Research Institute, at the Cost-Sharing Roundtable: Sustainable Strategies for Providing Access to Critical Medications. The event was co-hosted by the PAN Foundation and The American Journal of Managed Care®.
Presentation by Marcia Baker, MS, Ed, director, Corporate Development & Programs, Mended Hearts, Inc, the Cost-Sharing Roundtable: Sustainable Strategies for Providing Access to Critical Medications. The event was co-hosted by the PAN Foundation and The American Journal of Managed Care®.
Presentation by Andrea Baer, MS, director of Patient Advocacy, Mended Hearts, Inc, at the Cost-Sharing Roundtable: Sustainable Strategies for Providing Access to Critical Medications. The event was co-hosted by the PAN Foundation and The American Journal of Managed Care®.
Work presented by Veena Shankaran, MD, MS, associate professor, Division of Medical Oncology, University of Washington and associate member, Clinical Research Division, Fred Hutchinson Cancer Research Center, at the the Cost-Sharing Roundtable: Sustainable Strategies for Providing Access to Critical Medications. The event was co-hosted by the PAN Foundation and The American Journal of Managed Care®.
Melissa Thompson, MBA, healthcare strategist and a cancer patient, spoke at the Cost-Sharing Roundtable: Sustainable Strategies for Providing Access to Critical Medications. The event was co-hosted by the PAN Foundation and The American Journal of Managed Care®.
